Retrospective Analysis of the Epidemiological Change and Determinants of Prognosis of Talaromycosisof Human Immunodeficiency Virus Negative Host in Guangxi (RAECDPT)

Guangxi Medical University

Status: Unknown

Conditions: To Study the Recurrence Indicators and Establish a Therapeutic Effect Evaluation System of T. Marneffei Infections; To Investigate the Characteristics and Prognostic Factors of T. Marneffei Infections and the Causes of Misdiagnosis

Treatments: Other: the multiple programs of antifungal therapy for HIV-negative host

Study type: Observational

Funder types: Other

Identifiers

NCT03819348

RA-TSM-HIVN-ECDP

Details and patient eligibility

About

Through a multi-center large-sample retrospective study, the epidemiological changes of TSM in Guangxi have been reviewed, its incidence trend was understood to attract the attention of clinicians; the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators. Improve the level of understanding and diagnosis and treatment of HIV-negative TSM in the whole area. A comprehensive efficacy evaluation system and standard treatment program was established to provide a basis for standardized treatment of TSM in HIV-negative hosts. The observational indicators included: 2-week all-cause mortality; 24-week all-cause mortality; clinical improvement time; level of decrease of fungus in the blood culture medium two weeks before treatment; recurrence; appearance of adverse drug reaction at the level 3 and above.

Enrollment: 1,200 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Eligible patients were HIV-negative adults who had talaromycosis that was confirmed by either microscopy or culture.

Exclusion criteria

• patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.

Trial design

1,200 participants in 1 patient group

TSM of HIV-negative Host

Description:

Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.

Treatment:

Other: the multiple programs of antifungal therapy for HIV-negative host